Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy

Erkan Topkan, Huseyin Mertsoylu, Ahmet Kucuk, Ali Ayberk Besen, Ahmet Sezer, Duygu Sezen, Yasemin Bolukbasi, Ugur Selek, Berrin Pehlivan, Erkan Topkan, Huseyin Mertsoylu, Ahmet Kucuk, Ali Ayberk Besen, Ahmet Sezer, Duygu Sezen, Yasemin Bolukbasi, Ugur Selek, Berrin Pehlivan

Abstract

Background: We investigated the prognostic significance of pretreatment systemic inflammation response index (SIRI) in locally advanced pancreatic carcinoma (LAPC) patients treated with concurrent chemoradiotherapy (CRT).

Methods: Present retrospective cohort analysis investigated consecutive 154 LAPC patients who received radical CRT. The SIRI was defined as: SIRI = neutrophil × monocyte/lymphocyte counts. Ideal SIRI cutoff(s) influencing overall survival (OS) and progression-free survival (PFS) results were sought by using receiver operating characteristic (ROC) curve analysis. The primary endpoint was the interaction between the SIRI and OS results.

Results: The median follow-up, PFS, and OS durations were 14.3 (range: 2.9-74.6), 7.9 [%95 confidence interval (CI): 5.7-10.1), and 14.7 months (%95 CI: 11.4-18.0) for the entire cohort, respectively. ROC curve analyses determined the ideal SIRI cutoff that exhibiting a significant link with OS and PFS outcomes at the rounded 1.6 point (AUC: 74.3%; sensitivity: 73.8%; specificity: 70.1%).The SIRI <1.6 patients (N = 58) had significantly superior median PFS (13.8 versus 6.7 months; P < 0.001) and OS (28.6 versus 12.6 months; P < 0.001) lengths than SIRI ≥1.6 patients (N = 96), respectively. Although the N0 (versus N1; P < 0.05) and CA 19-9 ≤90 U/mL (versus >90 U/mL) appeared as the other significant associates of better OS and PFS in univariate analyses, yet the results of multivariate analyses confirmed the SIRI <1.6 as the independent indicator of superior OS and PFS (P < 0.001 for each).

Conclusion: Pretreatment SIRI is a novel independent prognosticator that may further enhance the conventional tumor-node-metastases staging system in a more precise prediction of the OS and PFS outcomes of LAPC patients after radical CRT.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2020 Erkan Topkan et al.

Figures

Figure 1
Figure 1
Receiver operating curve analyses outcomes: (a) progression-free survival, and (b) overall survival.
Figure 2
Figure 2
Survival outcomes per systemic inflammation response index (SIRI) groups: (a) progression-free survival, and (b) overall survival.

References

    1. Yeo T. P., Hruban R. H., Leach S. D., et al. Pancreatic cancer. Current Problems in Cancer. 2002;26(4):176–275. doi: 10.1067/mcn.2002.129579.
    1. Johung K., Saif M. W., Chang B. W. Treatment of locally advanced pancreatic cancer: the role of radiation therapy. International Journal of Radiation Oncology • Biology • Physics. 2012;82(2):508–518. doi: 10.1016/j.ijrobp.2011.08.008.
    1. Huguet F., Girard N., Guerche C. S.-E., Hennequin C., Mornex F., Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. Journal of Clinical Oncology. 2009;27(13):2269–2277. doi: 10.1200/JCO.2008.19.7921.
    1. Iacobuzio-Donahue C. A., Fu B., Yachida S., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. Journal of Clinical Oncology. 2009;27(11):1806–1813. doi: 10.1200/JCO.2008.17.7188.
    1. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013.
    1. Raimondi S., Lowenfels A. B., Morselli-Labate A. M., Maisonneuve P., Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Practice & Research. Clinical Gastroenterology. 2010;24(3):349–358. doi: 10.1016/j.bpg.2010.02.007.
    1. Martin H. L., Ohara K., Kiberu A., van Hagen T., Davidson A., Khattak M. A. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Internal Medicine Journal. 2014;44(7):676–682. doi: 10.1111/imj.12453.
    1. Birtolo C., Go V. L. W., Ptasznik A., Eibl G., Pandol S. J. Phosphatidylinositol 3-Kinase. Pancreas. 2016;45(1):21–31. doi: 10.1097/MPA.0000000000000531.
    1. Steele C. W., Jamieson N. B., Evans T. R. J., et al. Exploiting inflammation for therapeutic gain in pancreatic cancer. British Journal of Cancer. 2013;108(5):997–1003. doi: 10.1038/bjc.2013.24.
    1. Zambirinis C. P., Pushalkar S., Saxena D., Miller G. Pancreatic cancer, inflammation, and microbiome. Cancer Journal. 2014;20(3):195–202. doi: 10.1097/PPO.0000000000000045.
    1. McMillan D. C. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treatment Reviews. 2013;39(5):534–540. doi: 10.1016/j.ctrv.2012.08.003.
    1. Shimizu T., Taniguchi K., Asakuma M., et al. Lymphocyte-to-monocyte ratio and prognostic nutritional index predict poor prognosis in patients on chemotherapy for unresectable pancreatic cancer. Anticancer Research. 2019;39(4):2169–2176. doi: 10.21873/anticanres.13331.
    1. Xiao Y., Xie Z., Shao Z., et al. Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients. Medicine. 2017;96(50, article e9247) doi: 10.1097/MD.0000000000009247.
    1. Shirai Y., Shiba H., Haruki K., et al. Preoperative platelet-to-albumin ratio predicts prognosis of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Anticancer Research. 2017;37(2):787–794. doi: 10.21873/anticanres.11378.
    1. Yamada S., Fujii T., Yabusaki N., et al. Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow Prognostic Score is the most reliable parameter. Medicine. 2016;95(18, article e3582) doi: 10.1097/MD.0000000000003582.
    1. Qi Q., Zhuang L., Shen Y., et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. doi: 10.1002/cncr.30057.
    1. Pacheco-Barcia V., Mondéjar Solís R., France T., et al. A systemic inflammation response index could be a predictive factor for mFOLFIRINOX in metastatic pancreatic cancer. Pancreas. 2019;48(5):e45–e47. doi: 10.1097/MPA.0000000000001294.
    1. Chen Z., Wang K., Lu H., et al. Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis. Cancer Management and Research. 2019;11:909–919. doi: 10.2147/CMAR.S186976.
    1. Xu L., Yu S., Zhuang L., et al. Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients. Oncotarget. 2017;8(21):34954–34960. doi: 10.18632/oncotarget.16865.
    1. Chen Y., Jiang W., Xi D., et al. Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas. Journal of Investigative Medicine. 2019;67(3):691–698. doi: 10.1136/jim-2018-000801.
    1. Geng Y., Zhu D., Wu C., et al. A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma. International Immunopharmacology. 2018;65:503–510. doi: 10.1016/j.intimp.2018.10.002.
    1. Topkan E., Yavuz A. A., Aydin M., Onal C., Yapar F., Yavuz M. N. Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. Journal of Experimental & Clinical Cancer Research. 2008;27(1):p. 41. doi: 10.1186/1756-9966-27-41.
    1. Yildirim B. A., Ozdemir Y., Colakoglu T., Topkan E. Impact of presence and degree of pretreatment weight loss in locally-advanced pancreatic cancer patients treated with definitive concurrent chemoradiotherapy. Pancreatology. 2016;16(4):599–604. doi: 10.1016/j.pan.2016.03.006.
    1. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Journal of the American Medical Association. 2007;297(3):267–277. doi: 10.1001/jama.297.3.267.
    1. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? The Lancet. 2001;357(9255):539–545. doi: 10.1016/S0140-6736(00)04046-0.
    1. Germano G., Allavena P., Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine. 2008;43(3):374–379. doi: 10.1016/j.cyto.2008.07.014.
    1. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi: 10.1038/nature07205.
    1. Coussens L. M., Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi: 10.1038/nature01322.
    1. Elinav E., Nowarski R., Thaiss C. A., Hu B., Jin C., Flavell R. A. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nature Reviews. Cancer. 2013;13(11):759–771. doi: 10.1038/nrc3611.
    1. Suker M., Beumer B. R., Sadot E., et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. The Lancet Oncology. 2016;17(6):801–810. doi: 10.1016/S1470-2045(16)00172-8.
    1. Wang C., Liu X., Wang X., Wang Y., Cha N. Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: a meta-analysis of randomized controlled trials. Medicine. 2018;97(36, article e12260) doi: 10.1097/MD.0000000000012260.
    1. Mukherjee S., Hurt C. N., Bridgewater J., et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. The Lancet Oncology. 2013;14(4):317–326. doi: 10.1016/S1470-2045(13)70021-4.
    1. Balkwill F. R., Capasso M., Hagemann T. The tumor microenvironment at a glance. Journal of Cell Science. 2013;125(23):5591–5596.
    1. Ferrone C., Dranoff G. Dual roles for immunity in gastrointestinal cancers. Journal of Clinical Oncology. 2010;28(26):4045–4051. doi: 10.1200/JCO.2010.27.9992.
    1. Diakos C. I., Charles K. A., McMillan D. C., Clarke S. J. Cancer-related inflammation and treatment effectiveness. The Lancet Oncology. 2014;15(11):493–503.
    1. Shibutani M., Maeda K., Nagahara H., et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. World Journal of Gastroenterology. 2015;21(34):9966–9973. doi: 10.3748/wjg.v21.i34.9966.
    1. Aziz M. H., Sideras K., Aziz N. A., et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: A retrospective multicenter cohort study. Annals of Surgery. 2019;270(1):139–146. doi: 10.1097/SLA.0000000000002660.
    1. Azar I., Virk G., Esfandiarifard S., Wazir A., Mehdi S. Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study. Journal of Gastrointestinal Oncology. 2019;10(4):703–711. doi: 10.21037/jgo.2018.07.08.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir